The American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH) first published their guidelines on erythropoiesis-stimulating agents (ESAs) in cancer care in 2002, with updates in 2007 and 2010, and the new update is the first to address biosimilar epoetin alfa.
The American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH) have issued an updated practice guideline on the use of erythropoiesis-stimulating agents (ESAs) in cancer care in which they state that the available literature suggests that biosimilars of epoetin alfa have similar efficacy and safety to reference agents and that both biosimilars and their references may be offered to patients with chemotherapy-associated anemia whose cancer treatment is not curative in intent.
ASCO and ASH first published their guidelines on ESAs in cancer care in 2002, with updates in 2007 and 2010, and the new update is the first to address biosimilar epoetin alfa.
In producing the 2019 guideline update, ASCO and ASH reviewed randomized controlled trials and meta-analyses on ESAs used in treating patients with cancer or chronic kidney disease, as well as cohort studies in patients with cancer, focusing on literature published between 2010 and 2018. An expert panel was convened to assess the evidence and revise previous recommendations.
With respect to biosimilars, hemoglobin response and immunogenicity were outcomes of interest in addition to the primary outcomes of mortality, frequency of red blood cell transfusion, thromboembolic risk, and progression-free survival.
The new guideline includes the moderate recommendation, on the basis of intermediate-quality evidence, that epoetin beta and alfa, darbepoetin, and biosimilar epoetin alfa are all equivalent with respect to their safety and efficacy.
“Based on limited evidence, it seems that compared with the originator, biosimilars of epoetin alfa are safe and effective,” write the authors. They add that biosimilar ESAs have been used in Europe for more than a decade without major concerns having arisen.
“Ultimately, the choice of a particular agent will depend on cost, availability, convenience, and personal considerations or preference,” they write.
Reference
Bohlius J, Bohlke K, Castelli R, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Advances. 2019;3:1197-1210. doi: 10.1182/bloodadvances.2018030387.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.